Article Text
PDF
Abstract
Background Acute pyelonephritis in children may result in permanent kidney scarring that is primarily caused by inflammation during acute infection. Antibiotic therapy alone is not enough to significantly reduce kidney scarring, and adjuvant corticosteroid therapy has shown a significant reduction in inflammatory cytokines in urine prompting its evaluation in randomised controlled trials. A few clinical trials showed a trend towards a reduction in renal scarring but did not have an adequate sample size to show a significant effect. Therefore, we planned to synthesise the available evidence on the role of corticosteroids as adjuvant therapy in reducing kidney scarring.
Objective To assess the efficacy and safety of adjuvant corticosteroid therapy for the prevention of kidney scarring in children with acute pyelonephritis.
Design Systematic review and meta-analysis.
Setting Community-acquired febrile urinary tract infections.
Patients Children (less than 18 years) with acute pyelonephritis.
Intervention Adjuvant corticosteroid therapy (along with antibiotic treatment).
Main outcome measures Primary: efficacy in preventing kidney scarring; secondary: serious adverse events associated with corticosteroid therapy.
Results Three randomised trials (529 children) were included. Corticosteroids are effective in lowering the risk of kidney scarring as compared with placebo (risk ratio (RR): 0.57; 95% CI 0.36 to 0.90). No significant increase risk of bacteraemia (RR: 1.38; 95% CI 0.23 to 8.23) and hospitalisation (RR: 0.87; 95% CI 0.3 to 2.55) was observed in corticosteroid group.
Conclusion Moderate quality evidence suggests that short duration ‘adjuvant corticosteroid therapy’ along with routine antibiotic therapy in acute febrile urinary tract infection significantly reduces the risk of kidney scarring without any significant adverse effects.
- nephrology
- therapeutics
Data availability statement
Data sharing is not applicable as no datasets generated and/or analysed for this study. The study is a systematic review; thus, data sharing is not applicable.
Statistics from Altmetric.com
Data availability statement
Data sharing is not applicable as no datasets generated and/or analysed for this study. The study is a systematic review; thus, data sharing is not applicable.
Footnotes
JM and JK contributed equally.
Contributors JM: conceptualised and designed the study, formulated search strategy, collected data and analysed the data and drafted the initial manuscript; JK: formulated search strategy, acquisition of data and critically revised the final manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.